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Background: Common cold is caused by a variety of respiratory viruses. The prevalence in children is high, and it
potentially contributes to significant morbidity. Iota-carragenan, a polymer derived from red seaweed, has reduced
viral load in nasal secretions and alleviated symptoms in adults with common cold.
Methods: We have assessed the antiviral and therapeutic activity of a nasal spray containing iota-carrageenan in
children with acute symptoms of common cold. A cohort of 153 children between 1–18 years (mean age 5 years),
displaying acute symptoms of common cold were randomly assigned to treatment with a nasal spray containing
iota-carrageenan (0.12%) as verum or 0.9% sodium chloride solution as placebo for seven days. Symptoms of
common cold were recorded and the viral load of respiratory viruses in nasal secretions was determined at two
consecutive visits.
Results: The results of the present study showed no significant difference between the iota carrageenan and the
placebo group on the mean of TSS between study days 2–7. Secondary endpoints, such as reduced time to
clearance of disease (7.6 vs 9.4 days; p = 0.038), reduction of viral load (p = 0.026), and lower incidence of secondary
infections with other respiratory viruses (p = 0.046) indicated beneficial effects of iota-carrageenan in this population.
The treatment was safe and well tolerated, with less side effects observed in the verum group compared to
placebo.
Conclusion: In this study iota-carrageenan did not alleviate symptoms in children with acute symptoms of
common cold, but significantly reduced viral load in nasal secretions that may have important implications for
future studies.
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Acute viral infection of the upper respiratory tract, also
referred to as common cold, is the most frequently ob-
served disease in humans. Respiratory viral infections lead
to more than 400.000 hospitalizations per year in children
below 18 years of age in the United States [1]. The consi-
derable morbidity and mortality in adults and infants
caused by respiratory viral infections has recently
been reviewed [2,3]. The morbidity caused by viral
upper respiratory tract infections (URTI) and the en-
suing complications are more pronounced in indivi-
duals with pre-existing respiratory conditions such as
asthma [4,5]. While numerous treatment approaches have
been claimed to reduce symptoms [6], no interventions
were conclusively demonstrated to display antiviral acti-
vity, and to effectively decrease the duration or severity of
manifestations. A recent review reported the lack of effi-
cacy of OTC (over-the-counter) cough and cold medi-
cines in children, and revealed their inability to reduce
the rate of severe adverse events [7]. Substances such as
diphenhydramine and codeine have been associated with
significant side effects in children, thus restricting the ap-
plicability of several currently available therapies [8]. Re-
cently, a potent antiviral effect against several respiratory
viruses was demonstrated for iota-carrageenan, a polymer
derived from red seaweed [9,10]. Carrageenan has been
shown to display antiviral activity against a range of ani-
mal viruses [11] and has been tested clinically for preven-
tion of sexually transmitted HIV-1 viral infections [12,13].
Iota-carrageenan has recently been shown to be a potent
inhibitor of papilloma virus in-vitro, even at concentra-
tions below 1 μg/ml [14]. Carrageenan has been used as
food additive for centuries. As an indigestible polysac-
charide extracted from red algae (seaweed), it was added
to foods as a gelling agent or emulsifier. In 1959, carra-
geenan was granted GRAS (Generally Recognized as Safe)
status in the United States, thus documenting the safety
of this substance. Carrageenan increases the viscosity
if applied as nasal spray, thereby prolonging the humidi-
fication of the nasal mucosa. In addition, the solution
forms a barrier by direct interaction of carrageenan with
viruses, such as human rhinoviruses, which are trapped
and inactivated by the polymer. Results of a recent pilot
study in 35 adult patients showed that application of a
nasal spray containing iota-carrageenan three times per
day alleviated symptoms of common cold and reduced the
viral load in the nasal mucosa. Hereby, the efficacy of Car-
rageenan was shown on local symptoms, whereas systemic
symptoms remained the same [15].
Based on these observations, the present study was
conducted to evaluate the antiviral efficacy of a nasal
spray containing iota-carrageenan in children, with re-
gard to alleviation of symptoms and sequelae of common
cold.Methods
A randomized, double blind placebo-controlled pilot stu-
dy was conducted in two study centers, the St. Anna Chil-
dren’s Hospital and a private pediatric clinic in Vienna,
Austria.
Total Symptom Score (TSS)
The TSS used was based on the evaluation of eight lea-
ding clinical features including the systemic symptoms
headache, muscle ache, chilliness (systemic symptom
score, SSS), and the local symptoms including sore
throat, blocked nose, runny nose, cough, and sneezing
(local symptom score, LSS), according to a published sco-
ring system [16]. Severity was rated on a four-point scale
with zero indicating the absence of symptoms, and scores
of 1 to 3 representing mild, moderate and severe symp-
toms, respectively.
Patients
Previously healthy, immunocompetent children and ado-
lescents between 1 and 18 years of age with symptoms
of acute rhinitis prevailing for less than 48 hours, and
a total symptom score (TSS) ≤9, were enrolled in the
study between January 2009 and January 2010. This low
symptom score of 9 was chosen as inclusion criterion
because a higher TSS would have led to the use of
more co-medications, potentially biasing the effect of
Carrageenan. Immunocompetence was evaluated clinical-
ly, including a history of less than 5 bacterial infections
per year without a stay on intensive care units and without
a history of any chronic disease. URTI was defined by the
presence of appropriate symptoms according to a scale
described above. Suspected bacterial infections, recent use
of antimicrobial drugs, and intranasal treatment at first
presentation were exclusion criteria. However, additional
medication could be prescribed in case of fever, bacterial
otitis, wheezing, persistent coughing or pneumonia upon
decision of the physician. In line with the Austrian legal
requirements, written informed consent was obtained
from children above 14 years of age and from their
legal guardians in all instances.
Study Procedures
At enrolment into the study (first visit), medical history
was recorded, physical examination was performed, and
samples for molecular virus testing were obtained by a
standardized aspiration of nasal secretions. The samples
were frozen and stored at −80°C until use. Patients were
assigned to receive a nasal spray containing either iota-
carrageenan (0.12% / 0.5% sodium chloride) or placebo
(0.9% sodium chloride) in a randomized and blinded
manner (allocation ratio 1:1), using simple (unrestricted)
randomisation. The concentration of iota-carrageenan
and sodium chloride for the study medication was chosen
Figure 1 Virus Distribution. The distribution of respiratory viruses
is shown in percent of total positive specimens. Parainfluenzavirus
includes subtypes 1–3; Coronavirus includes subtypes 229E and
OC43.
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study [15], using the optimal galenic composition. The
nasal spray containers were sequentially numbered. The
random allocation sequence was generated by an inde-
pendent statistician, the participants were enrolled by a
study nurse and the investigating pediatricians assigned
participants to the interventions. The children and/or
their legal guardians received a standardized diary for the
recording of symptoms and additional medication. A sin-
gle puff (0.14 ml) of the spray per nostril was to be admi-
nistered three times per day for a total of seven days. The
patients and parents were requested to record symptoms
permitting assessment of the TSS during the first week of
treatment. Over the following two weeks (days 8 to 21),
recording of the presence or absence of any symptoms
was requested for determination of disease duration.
Follow-up examination of the patients and collection of
nasal secretion samples for molecular virus testing were
performed three to five days into treatment (second visit).
Final examination and collection of symptom diaries for
the evaluation were carried out on the third visit after day
21. Molecular screening and quantitative assessment of
viral load were performed for respiratory viruses including
rhinovirus (RV), respiratory syncytial virus (RSV), human
metapneumovirus (MPV), influenza A (InfA) virus, influ-
enza B (InfB) virus, parainfluenzavirus (PIV1, PIV2, PIV3),
and coronaviruses (CoV) by methods described previously
[17,18] (for more detailed description of virus analysis see
Additional file 1).
Ethics Statement
The study has been approved by the local IRB Committee
named Ethikkommission St. Anna Kinderspital (project
approval number 190109). In line with the Austrian legal
requirements, written informed consent was obtained
from children above 14 years of age and from their
legal guardians in all instances. The study was performed
in compliance with the ICH E6 Note for Guidance on
Good Clinical Practices (CPMP/ICH/135/95)5, the princi-
ples of the Declaration of Helsinki, local drug regulations,
and standard operating procedures of the investigator,
sponsor and CROs involved. The study protocol and
attached documentation were approved by the responsible
Ethics Committee.
Statistics
Comparison between the verum and placebo groups was
done by means of Mann–Whitney U-tests for conti-
nuous variables and by means of Chi square tests for or-
dinal or nominal variables. The viral load was compared
using Student’s T-test after logarithmic transformation
of the data. For comparison of time to disease clearance,
the Log Rank (Mantel Cox) test was used. Calculation of
the required sample size was based on previous resultsobtained in adult patients [15], which indicated that data
from 70 individuals would be sufficient to obtain signifi-
cant results on the primary endpoint, the mean of TSS
on days 2 to 7 at the 5% significance level and 80 per-
cent power. It was decided to recruit at least 200 pa-
tients in order to be able to analyze an ITT (intention to
treat) population of at least 150 patients, with further
analysis of per protocol (PP) patients.Results
Viral pathogens detected in the patient cohorts
investigated
A total of 213 patients with clinically confirmed acute
symptoms of common cold were assessed for eligibility
within a one year study period (Figure 1). Patients` cha-
racteristics are shown in Table 1. The main reason for
exclusion was the failure to return the study documents,
and in a few cases withdrawal of consent. Ultimately,
153 children could be included in the ITTcohort, and were
analyzed accordingly. The majority of children (88.8%)
tested positive for at least one virus (mean 1.5; range 1–5)
at visits 1 or 2. The most frequently detected viral patho-
gen was human rhinovirus (46%) followed by coronavirus
(13%), influenza A virus (19%), influenza B virus (11%), hu-
man metapneumavirus (5%), parainfluenzavirus (5%) and
respiratory syncytial virus (1%). The number of viruses de-
tected in individual patient samples obtained at visits one
and two in both groups is displayed in Figure 2.
Table 1 Characteristics of 213 pediatric patients with acute symptoms of common cold
Characteristic Placebo n=104 Iota-Carrageenan=109
Mean age-years (std deviation) 5.3 (3.6) 4.6 (3.6)
Mean weight-kilograms (std deviation) 22.6 (12.2) 20 (12)
Mean height- centimeters (std deviation) 112.7 (24.1) 108.3 (24.7)
Male gender-total (%) 42 (40.4) 62 (56.9)
Body-Mass Index (std deviation) 17.3 (3.0) 17.3 (3.3)
Smoke exposure-total (%) 15 (14.4) 11 (10.2)
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In the 153 patients of the ITT cohort, no significant
differences were observed between verum and placebo
treatment with regard to the primary efficacy variable,
the mean of total symptom scores (TSS) on days 2 to 7
of the study (Figure 3, Additional file 2: Table S1). The
mean TSS between days 2–7 was 3.8 (SD 2.8) in the iota-
carrageenan group and 4.0 (SD 2.6) in the placebo group.
Pre-defined secondary endpoints including TSS on diffe-
rent study days, total systemic and total local symptom
scores also showed no significant differences between the
iota-carrageenan and the placebo group (Figure 3B-E).
Detailed symptom-diaries were only requested during
the first week of the study. Between days 8–21, only the
presence or absence of common cold symptoms had to
be recorded. At the end of the study period of 21 days, a
significantly higher proportion of patients receiving pla-
cebo (12/77; 15.6%) reported symptoms in comparison
to only 3/77 (3.9%) patients in the group treated by
verum (p < 0.016). Moreover, the mean time to persistent
symptom alleviation reported by patients in the verum-Figure 2 Symptom scores in the ITT and PP cohort.treated group was significantly shorter in comparison
to the placebo group (7.6 versus 9.4 days; p = 0.038)
(Figure 4A). A post hoc analysis in patients with the most
commonly observed viral pathogens including rhinovirus
(n= 90) and coronavirus (n= 35) revealed a similar advan-
tage for the verum-treated group (Figures 4B and 4C).
The use of the nasal sprays was well tolerated. The
overall frequency of drug-related adverse events tended
to be lower in the iota-carrageenan group compared
to placebo. In the study period, adverse events rela-
ted to the upper respiratory tract were most common.
Treatment-unrelated severe adverse events (SAEs) were
observed in four patients, including two in the iota-
carrageenan group and two in the placebo group.
Monitoring of viral load and secondary infections
A secondary objective of the study was to investigate the
effect of iota-carrageenan nasal spray on virus elimi-
nation in nasal fluid samples. The incidence of viruses
observed was typical for common cold (Figure 2). To-
pical application of the iota-carrageenan spray reduced
viral loads in nasal secretions to a significantly higher
degree than placebo after 3 to 5 days of treatment
(p= 0.026; Figure 5), and the documented reduction in the
number of viruses between visits 1 and 2 was significantly
greater in the verum group. The antiviral efficacy of iota-
carrageenan is further supported by the fact that 27% of
patients in the verum group and less than 13% in the
placebo group tested virus-negative at the second visit
(Additional file 3: Figure S1B). The observed decrease
in virus-positive patients between visits 1 and 2 was statis-
tically significant only in the verum group (p < 0.001 ver-
sus p= 0.804). At the second visit, the mean number of
viruses detected in the iota-carrageenan group was
reduced from 1.3 to 0.8 (p < 0.001), while in the placebo
group the observed reduction from 1.3 to 1.1 was not sig-
nificant. Moreover, 52.2% of verum patients and 32.4%
placebo patients had cleared their viruses by the second
visit (p= 0.030). At visit 2, the incidence of newly acquired
infections with viruses that had not been detected at visit
1 was significantly lower in the verum group (13% versus
27%; p= 0.046).
Figure 3 Enrollment and randomization scheme.
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Figure 4 Alleviation of symptoms in patients with early
symptoms of common cold treated either with iota-
carrageenan nasal spray or placebo nasal spray. Alleviation was
defined as persistent disappearance of symptoms during the
observation period. Patients with recurrent disease were rated as
symptomatic until complete resolution of symptoms. (A) Cumulative
percentage of patients from the ITT population with complete
persistent alleviation of symptoms (p < 0.038). (B) Rhinovirus-positive
patients (n.s. p = 0.06). (C) Coronavirus-positive patients (p < 0.002).
P-values were determined by the Log-rank (Mantel-Cox) test.
Figure 5 Reduction of viral load between visits 1 and 2. The
log10 of the virus copies was determined by quantitative PCR
analysis, and the difference in viral load between visits was
calculated for the verum and the placebo group. The log10
difference in total virus copy number (±SEM) between visits 1 and 2
is shown (p < 0.026).
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Most patients (90%) received at least one additional drug
compatible with the study protocol as concomitant me-
dication, including non-steroidal anti-inflammatory agents
(64%), antitussives (57%), antibiotics (23%), ß2-sympa-
thomimetics (23%), and others (12%) (Additional file 3:
Figure S1). To address the notion that less co-
medication could permit better appreciation of the effect
of iota-carrageenan, a post hoc analysis was conducted in
a subgroup of patients (n= 51) who received either no co-
medication (n= 14) or one additional drug only (n= 37).
Patients receiving verum showed a trend towards lower TSS
compared to placebo-treated patients (Additional file 3:
Figure S1B).
Discussion
The need for therapeutic strategies against URTI in chil-
dren is highlighted by results of randomized studies on
the use of OTC preparations for treatment of common
cold in children below 12 years of age, which revealed no
significant differences between verum and placebo [19].
Due to insufficient data on the application of nasal de-
congestants for common cold in children, their use is
not recommended in patients below 12 years of age [20].
Upper respiratory tract infections in early childhood can
contribute to significant morbidity resulting from respira-
tory complications even in immunocompetent individuals.
To date, no causal therapy is available in most instances,
because URTIs are caused predominantly by viral patho-
gens for which no effective therapeutic agents have been
available.
The results of the present study showed no signifi-
cant difference between the iota-carrageenan and the
placebo group on the predefined primary endpoint, the
mean of TSS between study days 2–7. This may be
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necessary to avoid a bias by a higher use of co-medications.
Furthermore, the concentration of iota-carrageenan which
was the same as used in the previous pilot study in adults
[15], may also have an influence on symptom scores. About
90% of children in both study groups received one or more
co-medications. In the verum group, predominantly antiin-
flammatory agents (58%) or antitussives (62%), and less fre-
quently antibiotics (27%) or ß2-sympathomimetics (26%)
were prescribed. It is conceivable that the systemic and the
local symptom scores were respectively affected by the anti-
pyretic and the antitussive medication; hence negative
effects of the unusually high prevalence of patients with
multiple co-medications may have masked the effect of the
study medication.
The age of the patients in our study ranged between
one and 18 years, with a mean of five years. In young
children, it is often very difficult to evaluate symptoms
like headache, muscle ache or chilliness. These difficulties
in evaluating symptoms in children were recently dis-
cussed by Taylor et al. [21], and require careful conside-
ration in future studies in pediatric patient cohorts.
However, the mean difference in time to complete
symptom alleviation between the verum and the placebo
group was 1.8 days, while the reported effect of neur-
aminidase inhibitors on the treatment of influenza in
adults showed an overall benefit over placebo treatment
of approximately one day [22].
Another secondary objective of the study was determi-
nation of the viral pathogens and intranasal viral loads. Re-
cent data demonstrated that specific viral infections and
co-infections as well as viral load contribute to disease se-
verity in children with respiratory infections [23–25]. The
viruses detected in our study were similar to earlier reports,
and did not reveal constellations associated with a particu-
larly high risk of complications. Significantly more children
in the verum group tested virus-negative at visit 2, and
fewer children displayed multiple viruses or revealed a
new viral infection at this time. These findings may
have important implications. Recurrent viral episodes
prolonging reactive bronchial inflammation are frequently
encountered complications of URTI. In this regard, the
topical effect of iota-carrageenan could be instrumental by
reducing the incidence of subsequent lower respiratory
tract involvement.
The major limitations of this study include the restricted
performance of no more than two nasal aspirations, be-
cause newly acquired viral infections after day 3–5 could
have occurred in the placebo group during the follow up
period, potentially changing the proportion of patients
with no symptoms. A second limitation may be given
by the TSS questionnaire, which may not be the most
appropriate for a study population with a mean age of
5 years.Despite the fact that viral load in nasal secretions were
reduced by iota-carrageenan, no significant alleviation of
symptoms in children with common cold could be ob-
served in this prospective, randomized, placebo-controlled
pediatric study.
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